1. Futagawa M, Okazaki T, Nakata E, Fukano C, Osumi R, Kato F, Urakawa Y, Yamamoto H, Ozaki T, Hirasawa A. Genotypes and phenotypes of neurofibromatosis type 1 patients in Japan: A Hereditary Tumor Cohort Study. Hum Genome Var. 2024;11(1):42.
2. Kawasaki Y, Sudo T, Tamura K, Hinoshita S, Hasuoka K, Miyawaki S, Matsutani N, Hirasawa A, Uchinuno A. Knowledge and Awareness of Cancer Genome Profiling Tests among Japanese Patients with Cancer. Clin Pract. 2024 ;14(5):2105-2115.
3. Shimada S, Yamada T, Minamoto A, Matsukawa M, Yabe I, Tada H, Oda K, Ueki A, Higashigawa S, Morikawa M, Sato Y, Hirasawa A, Ogawa M, Kondo T, Yoshioka M, Kanai M, Muto M, Kosugi S. Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsy.J Hum Genet. 2025 Jan;70(1):33-40.
4. Piki E, Dini A, Rantanen F, Bentz F, Paavolainen L, Barker H, Raivola J, Hirasawa A, Kallioniemi O, Murumägi A, Ungureanu D. Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.Mol Ther Oncol. 2024 Nov 8;32(4):200903.
5. Nakamura W, Hirata M, Oda S, Chiba K, Okada A, Mateos RN, Sugawa M, Iida N, Ushiama M, Tanabe N, Sakamoto H, Sekine S, Hirasawa A, Kawai Y, Tokunaga K; NCBN Controls WGS Consortium; Tsujimoto SI, Shiba N, Ito S, Yoshida T, Shiraishi Y. Assessing the efficacy of target adaptive sampling long-read sequencing through hereditary cancer patient genomes.NPJ Genom Med. 2024;9(1):11.
6. Kage H, Akiyama N, Chang H, Shinozaki-Ushiku A, Ka M, Kawata J, Muto M, Okuma Y, Okita N, Tsuchihara K, Kikuchi J, Shirota H, Hayashi H, Kokuryo T, Yachida S, Hirasawa A, Kubo M, Kenmotsu H, Tanabe M, Ushiku T, Muto K, Seto Y, Oda K.Patient survey on cancer genomic medicine in Japan under the national health insurance system. Cancer Sci. 2024;115(3):954-962.
7. 平沢 晃. 多遺伝子パネル検査(MGPT)を用いた遺伝性腫瘍の診断 国内外における現状と課題(解説) 癌と化学療法2024; 51巻7号 Page677-680
8. 平沢 晃, 山本英喜. がんゲノム医療における多遺伝子パネル検査(MGPT)の導入にむけた現状と課題. 日本臨床検査医学会誌 2024; 434-437.